Back to Journals » Therapeutics and Clinical Risk Management » Volume 19
Original Research
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Economic Evaluation for Palbociclib Plus Fulvestrant vs Ribociclib Plus Fulvestrant and Abemaciclib Plus Fulvestrant in Endocrine-Resistant Advanced or Metastatic Breast Cancer in Italy
Total article views | HTML views | PDF downloads | Totals | ||
---|---|---|---|---|---|
4,259 | Dovepress* | 3,838+ | 132 | 3,970 | |
PubMed Central* | 421 | 193 | 614 | ||
Totals | 4,259 | 325 | 4,584 | ||
*Since 28 March 2023 |
Total mentioned | Delicious | Others | |||
---|---|---|---|---|---|
2 | 0 | 0 | 0 | 1 | 1 |
View citations on PubMed and Google Scholar